These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 35583797)

  • 1. Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).
    Guo L; Li L; Yu Q; Wang N; Chen J; Wang Z; Ding Y
    Diabetes Ther; 2022 Jun; 13(6):1231-1244. PubMed ID: 35583797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study.
    Seo JY; Lee CG; Choi H; Lee HK; Lee SY; Kim HJ; Jung KY; Kim JT
    Ann Pediatr Endocrinol Metab; 2023 Dec; 28(4):296-301. PubMed ID: 36758973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
    Zhou Y; Zhu J; Wu H; Deng Y; Ji Q
    Diabetes Ther; 2021 Oct; 12(10):2677-2690. PubMed ID: 34453682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
    Lee J; Cho YK; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Syndr Obes; 2019; 12():2745-2753. PubMed ID: 31920354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
    Yu M; Yuan GY; Zhang B; Wu HY; Lv XF
    Diabetes Ther; 2020 May; 11(5):1147-1159. PubMed ID: 32277401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
    Xu J; Zhang Y; Li Y; Zhao X; Zhou W; Loghin C; Tham LS; Cui X; Cui Y; Wang W
    Adv Ther; 2022 Jan; 39(1):488-503. PubMed ID: 34787823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dulaglutide: A Review in Type 2 Diabetes.
    Burness CB; Scott LJ
    BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Oct; 47(11):1206-1211. PubMed ID: 27917557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
    Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
    Yoon JH; Hong AR; Choi W; Park JY; Kim HK; Kang HC
    Chonnam Med J; 2021 Sep; 57(3):211-218. PubMed ID: 34621642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.
    Lee DSU; Lee H
    J Diabetes Res; 2023; 2023():7917641. PubMed ID: 37305431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Dulaglutide-Induced Vaginal Bleed.
    Vaccaro CJ; Zaidi SMH; Iskander PA; McFadden E
    Cureus; 2023 May; 15(5):e38774. PubMed ID: 37303364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
    Boye KS; Sapin H; García-Pérez LE; Rosilio M; Orsini Federici M; Heitmann E; Jung H; Aigner U; Guerci B; Giorgino F; Norrbacka K
    Diabetes Ther; 2020 Oct; 11(10):2383-2399. PubMed ID: 32880876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.